Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Niels C. Riedemann
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Beta
- 2.61
- Country
- DE
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.64
Financials
Revenue
$0.00-100.0%Net Income
$-10.65MEBITDA
$-10.63MFree Cash Flow
$-2.60MEPS (diluted)
$-0.09Shares Outstanding (diluted)
117.66M+402.6%Operating Expenses
$7.32MCash & Debt
$158.45MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.3K | $-45.63M | $-0.66 |
| 2024 | $165.8K | $-46.06M | $-0.78 |
| 2023 | $63.1K | $-42.67M | $-0.78 |
| 2022 | $0.00 | $-29.48M | $-0.61 |
| 2021 | $0.00 | $-45.63M | $-1.10 |
| 2020 | $0.00 | $-33.98M | $-1.26 |
| 2019 | $0.00 | $-53.25M | $-1.91 |
| 2018 | $0.00 | $-29.82M | $-1.19 |
| 2017 | $0.00 | $-24.24M | $-1.03 |
| 2016 | $0.00 | $-8.94M | $-0.38 |
| 2015 | $0.00 | $-4.92M | $-0.21 |
Valuation
IFRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·4d ago·Neutral
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.
View source ↗ - Newsglobenewswire.com·15d ago·Negative
InflaRx to Host Virtual Capital Markets Day Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
InflaRx Announces Participation in September Investor Conferences Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.07 per share
Typical surprise +5.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.07miss
- Thu, May 7$-0.09 vs $-0.17beat
- Thu, Mar 19$-0.17 vs $-0.18beat
- Mon, Nov 10$-0.16 vs $-0.16beat
- Thu, Aug 7$-0.24 vs $-0.24beat
- Wed, May 7$-0.14 vs $-0.18beat
Estimates and results for IFRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IFRX officers and directors.
No open-market trades in the recent filings. All 60 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IFRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.